Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the Lung

NCT05717140 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05717140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the Lung
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Withdrawn
Start date
October 28, 2025
Completion date
January 28, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv cutaneous melanoma ajcc v8, metastatic malignant neoplasm in the lung, metastatic melanoma, recurrent melanoma, unresectable melanoma